|Table of Contents|

Changes of T lymphocyte subsets before and after concurrent radiochemotherapy in high-grade glioma and its relationship with prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 05
Page:
829-833
Research Field:
Publishing date:

Info

Title:
Changes of T lymphocyte subsets before and after concurrent radiochemotherapy in high-grade glioma and its relationship with prognosis
Author(s):
LI Shan; ZHAO Yanjie; ZHAO Yuze; WANG Shuo; SHI Qi; HUANG Hongyan
Department of Oncology,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China.
Keywords:
glioma; radiochemotherapy; T lymphocyte subsets; prognosis
PACS:
R739.4
DOI:
10.3969/j.issn.1672-4992.2024.05.008
Abstract:
Objective:To observe the changes of T lymphocyte subsets before and after concurrent radiochemotherapy in high-grade glioma patients and analyze its relationship with prognosis.Methods:We retrospectively collected blood samples from 62 high-grade glioma patients who were treated in Beijing Shijitan Hospital from January 2016 to December 2022 and 30 healthy individuals as controls.5 mL of peripheral blood was collected from patients before and after concurrent chemoradiotherapy,and use flow cytometry to detect the level of T lymphocyte subsets(CD3+/CD4+,CD3+/CD8+,CD8+/CD28-,CD8+/CD28+).Results:The levels of CD3+/CD4+ cells were lower in patients compared with the healthy control group(P=0.027).After chemoradiation,the percentage of CD3+/CD4+ cells and CD8+/CD28- significantly declined,while the percentage of CD3+/CD8+ cells increased,the differences of CD3+/CD4+,CD8+/CD28- and CD3+/CD8+ cells before and after concurrent radiochemotherapy were statistically significant(P＜0.05).The median overall survival of 62 patients was 31.9 months.Patients with an increased percentage of CD8+/CD28- cells before treatment had shorter survival than those without increased,29.3 versus 36.3 months,respectively(P=0.045).Conclusion:Concurrent chemoradiation changed the immune environment of glioma patients,an increased percentage of CD8+/CD28-T cells can be used as a prognostic indicator for poor survival in high-grade glioma patients.

References:

[1]ELIANA MARINARI,MATHILDE ALLARD,ROBIN GUSTAVE,et al.Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma［J］.Oncoimmunology,2020,9(1):1779990.
[2]SHRAIBMAN B,BARNEA E,KADOSH DM,et al.Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma［J］.Mol Cell Proteomics,2019,18(6):1270.
[3]THAMIRIS BECKER SC,NATHALIA G,PEDRO V,et al.Immunosuppression in gliomas via PD-1/PD-L1 axis and adenosine pathway［J］.Front Oncol,2021，15:10:617385.
[4]MARIKE L BROEKMAN,SYBREN L N MAAS,ERIK R ABELS,et al.Multidimensional communication in the microenvirons of glioblastoma［J］.Nat Rev Neurol,2018,14:482-495.
[5]DERIN B KESKIN,ANNABELLE J ANANDAPPA,JING SUN,et al.Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial［J］.Nature,2019,565(7738):234-239.
[6] RAVI MEDIKONDA,GAVIN DUNN,MARYAM RAHMAN,et al.A review of glioblastoma immunotherapy［J］.J Neurooncol,2021,151(1):41-53.
[7]CARMEN KUT,LAWRENCE KLEINBERG.Radiotherapy,lymphopenia and improving the outcome for glioblastoma:a narrative review［J］.Chin Clin Oncol,2023,12(1):4.
[8]CHONGSATHIDKIET P,JACKSON C,KOYAMA S,et al.Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors［J］.Nat Med,2018 24(9):1459-1468.
[9]KELLY M HOTCHKISS,JOHN H SAMPSON.Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor［J］.J Neurooncol,2021,151(1):55-62.
[10]WEI X HUFF,JAE HYUN KWON,MARIO HENRIQUEZ,et al.The evolving role of CD8+CD28- immunosenescent T cells in cancer immunology［J］.Int J Mol Sci,2019,20(11):2810.
[11]JONATHAN B LAMANO,LEONEL AMPIE,WINWARD CHOY,et al.Immunomonitoring in glioma immunotherapy:current status and future perspectives［J］.J Neurooncol,2016,127(1):1-13.
[12]YUNLONG ZHAO,CHRISTINE CARON,YA-YUANCHAN,et al.cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8+ T cell function and anti-tumor immunity［J］.Immunity,2023,56(6):1187-1203.e12.
[13]YE J,HUANG XX,EDDY C HSUEH,et al.Human regulatory T cells induce T-lymphocyte senescence［J］.Blood,2012,120(10):2021-2031.
[14]DANIELA FENOGLIO,LILIANA BELGIOIA,ALESSIA PARODI,et al.Development of exhaustion and acquisition of regulatory function by infiltrating CD8+CD28- T lymphocytes dictate clinical outcome in head and neck cancer［J］.Cancers,2021,13(9):2234.
[15]OLESJA FORNARA,JENNY ODEBERG,NINA WOLMER SOLBERG,et al.Poor survival in glioblastoma patients is associated with early signs of immunosenescence in the CD4 T-cell compartment after surgery［J］.Oncoimmunology,2015,4(9):e1036211.
[16]WEI X HUFF,MARPE BAM,JACK M SHIREMAN,et al.Aging- and tumor-mediated increase in CD8+CD28- T cells might impose a strong barrier to success of immunotherapy in glioblastoma［J］.Immunohorizons,2021,5(6):395-409.
[17]RYAN C AUGUSTIN,RIYUE BAO,JASON J LUKE,et al.Targeting Cbl-b in cancer immunotherapy［J］.J Immunother Cancer,2023,11(2):e006007.

Memo

Memo:
北京市自然科学基金教育委员会科技计划重点项目(编号：KZ2021100225029)
Last Update: 2024-01-30